Fresenius SE & Co. KGaA (0OO9) AI Stock Analysis

Fresenius SE & Co. KGaA

(LSE:0OO9)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Profitability recoveryThe return to positive net profitability, supported by solid operating and EBITDA margins, indicates that the business has rebuilt earnings power after the 2023 loss. If maintained across Helios, Kabi and FMC-related operations, this recovery can support reinvestment and strengthen financial resilience over the next several quarters.

Negative Factors

Weakening cash conversionPositive cash flow is being generated, but the decline in free cash flow and conversion at roughly half of net income reduce confidence that accounting earnings are translating consistently into distributable cash. Persistent working-capital or capital-spending demands could constrain debt reduction, investment, and shareholder returns.

Fresenius SE & Co. KGaA (0OO9) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 26.65B
Dividend Yield: 2.20%
Average Volume (3M): 256.70K
Price to Earnings (P/E): 17.4
Beta (1Y): 1.04
Revenue Growth: 5.30%
EPS Growth: 35.29%
Country: UK
Employees: 178,486
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Fresenius SE & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four m...

Fresenius SE & Co. KGaA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0OO9 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:FME	72Outperform	EUR 10.73B	12.17	7.21%	3.69%	-0.47%	48.60%
DE:DRW3	65Neutral	EUR 1.64B	11.16	10.20%	2.23%	5.06%	40.18%
DE:MED	64Neutral	EUR 251.75M	8.72	11.54%	0.75%	2.94%	-14.28%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:RHK	55Neutral	EUR 963.91M	22.50	3.18%	1.39%	4.91%	11.71%
DE:COP	53Neutral	EUR 1.50B	43.42	4.19%	1.74%	―	―

* General Sector Average

Performance Comparison

GB:0OO9 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0OO9	Fresenius SE & Co. KGaA	47.66	-0.41	-0.85%
DE:COP	CompuGroup Medical	28.45	4.30	17.83%
DE:DRW3	Draegerwerk AG & Co. KGaA	102.00	31.82	45.34%
DE:FME	Fresenius Medical Care AG & Co. KGaA	40.40	-3.51	-8.00%
DE:MED	MEDICLIN AG	5.30	1.68	46.37%
DE:RHK	RHON-KLINIKUM AG	14.40	2.49	20.95%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Fresenius SE & Co. KGaA AI Stock Analysis